双鹭药业
(002038)
| 流通市值：42.87亿 | | | 总市值：51.68亿 |
| 流通股本：8.52亿 | | | 总股本：10.27亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 390,749,800.38 | 251,479,393.18 | 136,840,808.89 | 623,643,928.9 |
| 营业收入 | 390,749,800.38 | 251,479,393.18 | 136,840,808.89 | 623,643,928.9 |
| 二、营业总成本 | 376,249,757.93 | 248,722,029.09 | 102,494,124.4 | 628,880,940.37 |
| 营业成本 | 165,484,900.65 | 98,689,626.75 | 49,786,229.25 | 236,087,807.4 |
| 税金及附加 | 6,016,866 | 4,488,470.86 | 1,326,444.04 | 7,531,302.93 |
| 销售费用 | 30,507,317.03 | 27,682,536.27 | 7,218,354.46 | 111,336,582.83 |
| 管理费用 | 119,463,567.66 | 80,922,586.52 | 36,569,755.79 | 163,360,080.83 |
| 研发费用 | 55,760,852.78 | 37,320,436.52 | 7,870,598.46 | 115,397,117.62 |
| 财务费用 | -983,746.19 | -381,627.83 | -277,257.6 | -4,831,951.24 |
| 其中:利息收入 | 2,152,951.6 | 1,440,105.87 | 752,689.43 | 4,709,187.17 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -446,488,621.79 | -312,539,601.67 | -140,953,884.1 | 353,806,373.8 |
| 加:投资收益 | 14,807,289.51 | 7,564,799.32 | 42,552.21 | 13,380,373.66 |
| 资产处置收益 | -5,453.92 | -5,846.42 | - | -46,020.43 |
| 资产减值损失(新) | - | - | - | -27,461,410.02 |
| 信用减值损失(新) | -4,186,060.95 | -3,267,227.88 | 210,335.87 | -621,146,864.78 |
| 其他收益 | 2,608,567.14 | 2,583,563.06 | 2,566,237.37 | 7,418,999.79 |
| 四、营业利润 | -418,764,237.56 | -302,906,949.5 | -103,788,074.16 | -279,285,559.45 |
| 加:营业外收入 | 5,826,061.84 | 5,436,890.1 | - | 4,331,449.81 |
| 减:营业外支出 | 9,546.17 | 6,659.83 | 4,474.45 | 3,190,127.81 |
| 五、利润总额 | -412,947,721.89 | -297,476,719.23 | -103,792,548.61 | -278,144,237.45 |
| 减:所得税费用 | -61,700,922.34 | -41,669,485.65 | -16,524,258.87 | 70,064,254.57 |
| 六、净利润 | -351,246,799.55 | -255,807,233.58 | -87,268,289.74 | -348,208,492.02 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -351,246,799.55 | -255,807,233.58 | -87,268,289.74 | -348,208,492.02 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -350,129,601.11 | -255,075,245.07 | -86,114,439.76 | -347,197,803 |
| 少数股东损益 | -1,117,198.44 | -731,988.51 | -1,153,849.98 | -1,010,689.02 |
| 扣除非经常损益后的净利润 | 19,672,638.83 | 3,749,902.37 | 32,690,516.05 | -46,130,021.46 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.34 | -0.25 | -0.08 | -0.34 |
| (二)稀释每股收益 | -0.34 | -0.25 | -0.08 | -0.34 |
| 八、其他综合收益 | - | - | - | -35,241,507.99 |
| 归属于母公司股东的其他综合收益 | - | - | - | -35,241,507.99 |
| 九、综合收益总额 | -351,246,799.55 | -255,807,233.58 | -87,268,289.74 | -383,450,000.01 |
| 归属于母公司股东的综合收益总额 | -350,129,601.11 | -255,075,245.07 | -86,114,439.76 | -382,439,310.99 |
| 归属于少数股东的综合收益总额 | -1,117,198.44 | -731,988.51 | -1,153,849.98 | -1,010,689.02 |
| 公告日期 | 2026-10-29 | 2026-08-26 | 2026-04-29 | 2026-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |